Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma-Reference-Cited by-同舟云学术

Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

Published:2023-03-30 Issue:6 Volume:58 Page:565-574
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Yamauchi Reika,Ito Takanori,Yoshio Sachiyo^ORCID,Yamamoto Takafumi,Mizuno Kazuyuki,Ishigami Masatoshi,Kawashima Hiroki,Yasuda Satoshi,Shimose Shigeo,Iwamoto Hideki,Yamazoe Taiji,Mori Taizo,Kakazu Eiji,Kawaguchi Takumi,Toyoda Hidenori,Kanto Tatsuya

Funder

AMED

Grants-in-Aid for Scientific Research

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

https://link.springer.com/content/pdf/10.1007/s00535-023-01985-w.pdf

Reference30 articles.

1. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62.

2. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer (2021).

3. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.

4. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

5. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–96.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study;Clinical Cancer Research;2024-04-05

2. Changes in serum tumor marker levels are efficient predictors of complete response in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab;2024-02-14

3. Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma;Frontiers in Immunology;2023-12-22